CPDD 78th Annual Scientific Meeting Program
2016-78th-CPDD-Program-Book-6-07-16FINAL
2016-78th-CPDD-Program-Book-6-07-16FINAL
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Tuesday, June 14<br />
SYMPOSIA<br />
XI.<br />
Not your average joint: Alternative methods of cannabis consumption<br />
Chairs: Adam Leventhal and Marcel O. Bonn-Miller<br />
With increasing legalization of cannabis, there has been a proliferation of the number<br />
and types of cannabis preparations and drug delivery devices available on the market.<br />
Consequently, smoking cannabis is no longer the exclusive route of cannabinoid<br />
consumption prominent in the population. Oral consumption of edible cannabis<br />
products, transdermal application of topical cannabinoid ointments, and vaporization<br />
of cannabis plant, oils, and liquid extracts via e-cigarettes and other electronic devices<br />
are becoming increasingly popular. Unfortunately, many drug dependence researchers,<br />
clinicians, and policy makers are unaware of this trend and the emerging science on<br />
alternative routes of cannabis administration. This symposium synthesizes laboratory,<br />
clinical, and population-based research on the pharmacology, clinical correlates, and<br />
epidemiology of cannabis consumption via alternative routes. Human laboratory<br />
research on the acute pharmacokinetic and pharmacodynamic dose-effects of oral<br />
cannabis will be presented and contrasted to prototypical drug effect profiles of<br />
cannabis smoking. Clinical research pertaining to use of various cannabis preparations<br />
among cannabis-dependent individuals and patients using for therapeutic and<br />
recreational purposes will be discussed. Survey data characterizing cannabis vaping in<br />
adolescent and adult cannabis users will be presented. Also discussed will be the<br />
epidemiology of cannabis use by route of consumption and novel data on the<br />
prevalence and mental health correlates of adolescent cannabis vaping and use of<br />
edible cannabis products. The session will close with a discussion of translation across<br />
basic, clinical, and epidemiologic perspectives, and implications for regulation.<br />
Wednesday, June 15<br />
XII:<br />
Medicinal chemistry of novel kappa opioid receptor ligands<br />
Chairs: F.I. Carroll and Thomas Prisinzano<br />
Every since the discovery of the potent and selective kappa opioid receptor antagonists<br />
nor-BNI and kappa opioid receptor agonist such as U69,593 as well as other<br />
antagonists and agonists of this receptor system there has been continuing interest in<br />
basic medicinal chemistry studies that this receptor plays in numerous biological<br />
processes. Animal behavioral studies have shown that both antagonists and agonists<br />
have high potential for treating substance abuse (nicotine, alcohol, cocaine,<br />
methamphetamine and opiates) as well as other CNS disorders (depression, anxiety,<br />
attention deficit hyperactivity disorder, pain, and others). This symposium will provide<br />
information concerning newer kappa opioid receptor ligands for treating substance<br />
abuse. The presentations will include studies directed towards 1) the effect of<br />
substitution for the tryptophan residue in the natural product CJ-15,208; 2) a better<br />
understanding of the medicinal chemistry properties of salvinorin A and analogs; 3)<br />
the optimization of biased kappa opioid receptor ligands; and 4) the effect of changing<br />
the 3,4-dimethyl-4-(3-hyrroxyphenyl)piperidine part of JDTic on its medicinal<br />
chemistry properties. The basic medicinal chemistry research information presented in<br />
these four presentations will provide a better understanding of how the kappa opioid<br />
receptor target will lead to potential pharmacotherapies for treatment of various<br />
substance abuse problems and other CNS disorders.